HM Oosterkamp
Netherlands Cancer Institute
18 Papers
29 Citations
HM Oosterkamp is an academic researcher from Netherlands Cancer Institute. The author has contributed to research in topics: Breast cancer & Bevacizumab. The author has an hindex of 9, co-authored 16 publications.
Chat about Author
Papers
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
Walter Taal,HM Oosterkamp,Annemiek M E Walenkamp,Hendrikus J. Dubbink,Laurens V. Beerepoot,Monique Hanse,Jan Buter,Aafke H. Honkoop,Dolf Boerman,Filip de Vos,Winand N.M. Dinjens,Roelien H. Enting,Martin J B Taphoorn,Franchette W P J van den Berkmortel,Rob L. H. Jansen,Dieta Brandsma,Jacoline E C Bromberg,Irene van Heuvel,René M. Vernhout,Bronno van der Holt,Martin J. van den Bent +20 more
TL;DR: The first randomised controlled phase 2 trial of bevacizumab in recurrent glioblastoma reported overall survival at 9 months, and the combined treatment was well tolerated.
725
An evaluation of the efficacy of topical application of salicylic acid for the treatment of familial cylindromatosis
HM Oosterkamp,H. Neering,Sebastian M.B. Nijman,Annette M.G. Dirac,W.J. Mooi,René Bernards,Thijn R Brummelkamp +6 more
TL;DR: In cell‐based assays, salicylate can prevent NF‐κB activation caused by loss of the cylindromatosis gene, suggesting that salicylic acid application might be a potential treatment for cylindROMatosis.
Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study
Mette S. van Ramshorst,Erik van Werkhoven,I.A.M. Mandjes,Margaret Schot,Jelle Wesseling,Marie Jeanne T.F.D. Vrancken Peeters,Jetske M. Meerum Terwogt,Monique M.E.M. Bos,HM Oosterkamp,Sjoerd Rodenhuis,Sabine C. Linn,Gabe S. Sonke +11 more
TL;DR: An anthracycline-free neo-adjuvant regimen of weekly paclitaxel, trastuzumab and carboplatin is highly effective in HER2-positive breast cancer with manageable toxicity.
22
Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04).
A.G.J. van Rossum,Marleen Kok,E. van Werkhoven,Mark Opdam,I.A.M. Mandjes,A.E. van Leeuwen-Stok,H. van Tinteren,A.L.T. Imholz,Johanneke E.A. Portielje,Monique M.E.M. Bos,A. van Bochove,Jelle Wesseling,E.J.T. Rutgers,Sabine C. Linn,HM Oosterkamp,Matador Trialists' Grp +15 more
TL;DR: With a median follow-up of 7 years, no significant differences in RFS and OS were observed between six adjuvant cycles of ddAC and TAC in high-risk breast cancer patients.
14
Changes in gene expression profiling due to primary chemotherapy in patients with locally advanced breast cancer
Juliane Hannemann,HM Oosterkamp,Cathy A.J. Bosch,Claudette E. Loo,Anke T. Witteveen,Arno Velds,E.J.T. Rutgers,Sjoerd Rodenhuis,M.J. van de Vijver +8 more
TL;DR: This study was designed to identify gene expression patterns in LABC that can predict response to neoadjuvant therapy with Adriamycine and Cyclophosphamide and to correlate expression profiles with response to the chemotherapy.
9